Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar

NeuroImage

Volumn 49, Issue 2, 2010, Pages 1406-1415

  la Fougère, Christian ^a,b   Böning, Guido ^a   Bartmann, Hero ^a   Wängler, Björn ^a   Nowak, Sebastian ^a   Just, Theresa ^a   Wagner, Erika ^a   Winter, Petra ^a   Rominger, Axel ^a   Förster, Stefan ^a   Gildehaus, Franz Josef ^a   Rosa Neto, Pedro ^b   Minuzzi, Luciano ^b   Bartenstein, Peter ^a   Potschka, Heidrun ^a   Cumming, Paul ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

18F FDG; 18F MPPF; microPET; P glycoprotein; Tariquidar

Indexed keywords

4 FLUORO N [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] N (PYRIDIN 2 YL)BENZAMIDE F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; SEROTONIN 1A ANTAGONIST; TARIQUIDAR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; DRUG TRANSPORT; DRUG UPTAKE; ENERGY METABOLISM; FEMALE; HEART LEFT VENTRICLE; IC 50; IMAGE ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; TEST RETEST RELIABILITY;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; P-GLYCOPROTEIN; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; REPRODUCIBILITY OF RESULTS; SEROTONIN ANTAGONISTS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 70749126309     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.09.048     Document Type: Article

References (58)

1. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
2. Aznavour N., Benkelfat C., Gravel P., Aliaga A., Rosa-Neto P., Bedell B., Zimmer L., and Descarries L. MicroPET imaging of 5-HT(1A) receptors in rat brain: a test-retest [(18)F]MPPF study. Eur. J. Nucl. Med. Mol. Imaging 36 1 (2008) 53-62
3. 11C-verapamil and PET. J. Nucl. Med. 49 (2008) 1328-1335
4. Bart J., Groen H.J., Hendrikse N.H., van der Graaf W.T., Vaalburg W., and de Vries E.G. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat. Rev. 26 (2000) 449-462
5. Bart J., Dijkers E.C., Wegman T.D., de Vries E.G., van der Graaf W.T., Groen H.J., Vaalburg W., Willemsen A.T., and Hendrikse N.H. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145 (2005) 1045-1051
6. Bellamy D. Dietary restriction-a procedure with an undefined goal: a critical review of two recent books. Gerontology 36 (1990) 99-103
7. Bentley J., Quinn D.M., Pitman R.S., Warr J.R., and Kellett G.L. The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. Cancer Lett. 115 (1997) 221-227
8. Brandt C., Bethmann K., Gastens A.M., and Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 24 (2006) 202-211
9. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., and Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 695-698
10. 18F-MPPF PET in healthy humans: a reliability study. J. Nucl. Med. 48 (2007) 1279-1288
11. 18F]fluoro-l-DOPA in the rat. Biochem. Pharmacol. 50 (1995) 943-946
12. 2,3 receptors in pig brain. Neuroimage 19 (2003) 1127-1136
13. Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., and van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des. 10 (2004) 1493-1503
14. Elsinga P.H., Hendrikse N.H., Bart J., van Waarde A., and Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging Biol. 7 (2005) 37-44
15. Fox E., and Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 7 (2007) 447-459
16. Gunn R.N., Lammertsma A.A., Hume S.P., and Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6 (1997) 279-287
17. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., Van der Graaf W.T., Willemsen A.T., Vaalburg W., and Franssen E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 124 (1998) 1413-1418
18. Higashi K., Ueda Y., Ikeda R., Kodama Y., Guo J., Matsunari I., Oguchi M., Tonami H., Katsuda S., and Yamamoto I. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl. Med. Commun. 25 (2004) 19-27
19. Ishiwata K., Kawamura K., Yanai K., and Hendrikse N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med. 48 (2007) 81-87
20. Lacan G., Plenevaux A., Rubins D.J., Way B.M., Defraiteur C., Lemaire C., Aerts J., Luxen A., Cherry S.R., and Melega W.P. Cyclosporine, a P-glycoprotein modulator, increases [(18)F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur. J. Nucl. Med. Mol. Imaging 35 12 (2008) 2256-2266
21. Landvogt C., Mengel E., Bartenstein P., Buchholz H.G., Schreckenberger M., Siessmeier T., Scheurich A., Feldmann R., Weglage J., Cumming P., Zepp F., and Ullrich K. Reduced cerebral fluoro-l-dopamine uptake in adult patients suffering from phenylketonuria. J. Cereb. Blood Flow Metab. 28 (2008) 824-831
22. Langer O., Bauer M., Hammers A., Karch R., Pataraia E., Koepp M.J., Abrahim A., Luurtsema G., Brunner M., Sunder-Plassmann R., Zimprich F., Joukhadar C., Gentzsch S., Dudczak R., Kletter K., Muller M., and Baumgartner C. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 48 (2007) 1774-1784
23. 18F]MPPF, a fluoro analog of WAY-100635. Nucl. Med. Biol. 25 (1998) 343-350
24. Lee G., and Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 21 (2004) 1313-1330
25. 11C]verapamil. J. Pharmacol. Exp. Ther. 316 (2006) 647-653
26. Lin Y.C., Ellingrod V.L., Bishop J.R., and Miller del D. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther. Drug Monit. 28 (2006) 668-672
27. 11C](R)-(-)-RWAY. Synapse 61 (2007) 96-105
28. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., and Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16 (1996) 834-840
29. Lorke D.E., Kruger M., Buchert R., Bohuslavizki K.H., Clausen M., and Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J. Nucl. Med. 42 (2001) 646-654
30. Loscher W., and Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6 (2005) 591-602
31. Luker G.D., Flagg T.P., Sha Q., Luker K.E., Pica C.M., Nichols C.G., and Piwnica-Worms D. MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential. J. Biol. Chem. 276 (2001) 49053-49060
32. 18F]MPPF-PET study. Brain 127 (2004) 900-913
33. 18F]MPPF interactions in rats using the YAP-(S)PET scanner and a beta-microprobe. Neuroimage 41 (2008) 823-834
34. Nehlig A., Vergnes M., Marescaux C., and Boyet S. Mapping of cerebral energy metabolism in rats with genetic generalized nonconvulsive epilepsy. J. Neural. Transm. Suppl. 35 (1992) 141-153
35. 18F]MPPF in rats. Eur. J. Pharmacol. 407 (2000) 273-280
36. 18F]MPPF. J. Nucl. Med. 41 (2000) 1830-1835
37. 1A receptors in the human brain. J. Nucl. Med. 42 (2001) 1025-1031
38. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, California, USA
39. 11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. Neuroimage 35 (2007) 38-46
40. Potschka H., Fedrowitz M., and Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12 (2001) 3557-3560
41. Riad M., Rbah L., Verdurand M., Aznavour N., Zimmer L., and Descarries L. Unchanged density of 5-HT(1A) autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine. Neuroscience 151 (2008) 692-700
42. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., and Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2 (2002) 191-196
43. Roe M., Folkes A., Ashworth P., Brumwell J., Chima L., Hunjan S., Pretswell I., Dangerfield W., Ryder H., and Charlton P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett. 9 (1999) 595-600
44. Rubins D.J., Melega W.P., Lacan G., Way B., Plenevaux A., Luxen A., and Cherry S.R. Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain. Neuroimage 20 (2003) 2100-2118
45. Schinkel A.H., Mol C.A., Wagenaar E., van Deemter L., Smit J.J., and Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 31A (1995) 1295-1298
46. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
47. Seegers U., Potschka H., and Loscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 43 (2002) 675-684
48. Seo S., Hatano E., Higashi T., Hara T., Tada M., Tamaki N., Iwaisako K., Ikai I., and Uemoto S. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin. Cancer Res. 13 (2007) 427-433
49. 1A receptors in humans. Synapse 25 (1997) 147-154
50. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006) 219-234
51. Theodore W.H., DiChiro G., Margolin R., Fishbein D., Porter R.J., and Brooks R.A. Barbiturates reduce human cerebral glucose metabolism. Neurology 36 (1986) 60-64
52. Toga A.W., Santori E.M., Hazani R., and Ambach K. A 3D digital map of rat brain. Brain Res. Bull. 38 (1995) 77-85
53. van Asperen J., Schinkel A.H., Beijnen J.H., Nooijen W.J., Borst P., and van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J. Natl. Cancer Inst. 88 (1996) 994-999
54. Volk H., Potschka H., and Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J. Histochem. Cytochem. 53 (2005) 517-531
55. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38 (2008) 802-832
56. Zimmer L., Pain F., Mauger G., Plenevaux A., Le Bars D., Mastrippolito R., Pujol J.F., Renaud B., and Laniece P. The potential of the beta-microprobe, an intracerebral radiosensitive probe, to monitor the [(18)F]MPPF binding in the rat dorsal raphe nucleus. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1237-1247
57. 1A autoreceptor internalization. Neuroimage 22 (2004) 1421-1426
58. 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J. Nucl. Med. 49 (2008) 649-656